


MIP-1095 TFA

Cat. No.:	HY-123733A
Molecular Formula:	C ₂₁ H ₂₆ F ₃ IN ₄ O ₁₀
Molecular Weight:	678.35
Target:	PSMA
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled (¹³¹I labeled) as an imaging probe to indicate tumor progression. And ¹³¹I-MIP-1095 showed higher renal uptake in mice^{[1][2]}.

REFERENCES

[1]. Zechmann CM, et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92.

[2]. Kelly JM, et al. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. J Nucl Med. 2017 Sep;58(9):1442-1449.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA